ATE395937T1 - Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere - Google Patents

Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere

Info

Publication number
ATE395937T1
ATE395937T1 AT03712655T AT03712655T ATE395937T1 AT E395937 T1 ATE395937 T1 AT E395937T1 AT 03712655 T AT03712655 T AT 03712655T AT 03712655 T AT03712655 T AT 03712655T AT E395937 T1 ATE395937 T1 AT E395937T1
Authority
AT
Austria
Prior art keywords
avidindimeres
concentration
increasing
effective
pretargeted radioimmunotherapy
Prior art date
Application number
AT03712655T
Other languages
English (en)
Inventor
Santis Rita De
Ragnar Lindstedt
Carlo Antonio Nuzzolo
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE395937T1 publication Critical patent/ATE395937T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT03712655T 2002-03-08 2003-03-06 Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere ATE395937T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002RM000128A ITRM20020128A1 (it) 2002-03-08 2002-03-08 Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Publications (1)

Publication Number Publication Date
ATE395937T1 true ATE395937T1 (de) 2008-06-15

Family

ID=11456156

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03712655T ATE395937T1 (de) 2002-03-08 2003-03-06 Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere

Country Status (21)

Country Link
US (2) US7425317B2 (de)
EP (1) EP1482981B1 (de)
JP (1) JP4362376B2 (de)
KR (1) KR100993626B1 (de)
CN (1) CN1638807B (de)
AR (1) AR038897A1 (de)
AT (1) ATE395937T1 (de)
AU (1) AU2003217467B2 (de)
BR (1) BR0308117A (de)
CA (1) CA2475534C (de)
CY (1) CY1108268T1 (de)
DE (1) DE60321142D1 (de)
DK (1) DK1482981T3 (de)
ES (1) ES2302917T3 (de)
IT (1) ITRM20020128A1 (de)
MX (1) MXPA04008639A (de)
PL (1) PL372721A1 (de)
PT (1) PT1482981E (de)
SI (1) SI1482981T1 (de)
TW (1) TWI345982B (de)
WO (1) WO2003075960A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1317303C (zh) 2002-02-26 2007-05-23 希格马托制药工业公司 抗人腱生蛋白单克隆抗体
ITRM20020128A1 (it) * 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
JP2008064475A (ja) * 2006-09-04 2008-03-21 Osaka Univ 標的物質の高感度検出方法、検出用キットおよび検出装置
JP2016511747A (ja) 2013-01-04 2016-04-21 マサチューセッツ インスティテュート オブ テクノロジー ナノ粒子表面結合に基づく薬物の組織への送達
CN105214843A (zh) * 2015-10-20 2016-01-06 东莞市利发爱尔空气净化系统有限公司 一种高压放电单元及空气净化器

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687732A (en) * 1983-06-10 1987-08-18 Yale University Visualization polymers and their application to diagnostic medicine
CA2134239C (en) * 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
ITRM20020128A1 (it) 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
US7807133B2 (en) 2010-10-05
CA2475534A1 (en) 2003-09-18
AU2003217467B2 (en) 2008-06-26
US20050106102A1 (en) 2005-05-19
CN1638807B (zh) 2010-05-26
BR0308117A (pt) 2005-01-04
TWI345982B (en) 2011-08-01
JP4362376B2 (ja) 2009-11-11
ES2302917T3 (es) 2008-08-01
EP1482981A1 (de) 2004-12-08
CA2475534C (en) 2011-06-14
ITRM20020128A0 (it) 2002-03-08
AU2003217467A1 (en) 2003-09-22
DK1482981T3 (da) 2008-09-01
ITRM20020128A1 (it) 2003-09-08
SI1482981T1 (sl) 2008-08-31
DE60321142D1 (de) 2008-07-03
EP1482981B1 (de) 2008-05-21
AR038897A1 (es) 2005-02-02
PL372721A1 (en) 2005-07-25
CY1108268T1 (el) 2014-02-12
MXPA04008639A (es) 2004-12-06
KR100993626B1 (ko) 2010-11-11
HK1078462A1 (en) 2006-03-17
US7425317B2 (en) 2008-09-16
JP2005529081A (ja) 2005-09-29
WO2003075960A1 (en) 2003-09-18
CN1638807A (zh) 2005-07-13
US20090010839A1 (en) 2009-01-08
KR20040093067A (ko) 2004-11-04
TW200306207A (en) 2003-11-16
PT1482981E (pt) 2008-07-15

Similar Documents

Publication Publication Date Title
CY2018009I2 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
DE60328426D1 (de) Gestaltung der Verschlusselemente
DE60323875D1 (de) Eine atp-rückzykluslänge verwendende vorrichtung zur unterscheidung von arrythmien
PL374323A1 (pl) Porowaty materiał na bazie węglika krzemu oraz sposób wytwarzania go
NL1024643A1 (nl) Purineverbindingen en gebruik daarvan.
FR2842416B1 (fr) Composition cosmetique
NO20023050L (no) Fremgangsmåte samt anlegg for utf degree relse av fremgangsmåten
NO20025123D0 (no) Vann-silisiumoksyd-suspensjoner for bruk i brönnsement
EP1559433A4 (de) Stabilisierte zusammensetzung
FI20031453L (fi) Järjestely ja menetelmä tiedon tarjoamiseksi käyttäjälle
SE0500163L (sv) Sammansättning
DE60322926D1 (de) Photopolymerisierbare zusammensetzung und verwendung davon
NO20024880D0 (no) Sammensetning inneholdende fosfat
TWI345982B (en) Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
EP1532193A4 (de) Organosiloxane
FI20031458A0 (fi) Kantopakkaus ja pakkauksen kantorakenne
NO20052356D0 (no) Redningsskoyte
DE50308413D1 (de) Kontaktierung von nanoröhren
ATE404661T1 (de) Transdifferenzierung von pankreas- acinuszellen
SE0200401D0 (sv) Strömriktare samt användning därav
DE502004010900D1 (de) Sitz zur Beförderung von Personen
DK1529034T3 (da) Benzoylpyrazoloner substitueret med 3-aminocarbonyl
SE0202567D0 (sv) Spiropiperidine compounds and their use
SE0202625D0 (sv) New Composition use and method
NO20021576D0 (no) Flytebro

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1482981

Country of ref document: EP